Stemline Therapeutics Inc.

stemline therapeutics, inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. stemline is developing three clinical stage product candidates, sl-401, sl-701, and sl-801. a phase 2 potentially pivotal trial with sl-401, a targeted therapy directed to the interleukin-3 receptor (cd123) present on a wide range of hematologic cancers, is enrolling patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn) for which it has received breakthrough therapy designation from the u.s. food and drug administration (fda). data from this ongoing trial have demonstrated high overall response rates (orr), with multiple complete responses (crs). patients are being followed for response duration and outcomes, and new patients continue to enroll into the study. in addition, ongoing phase 2 trials with sl-401 are currently enrolling patients with additional malignancies including acute myeloid leukemia (aml) in remission with high risk for relapse including minim